Formation Mechanism, In vitro and In vivo Evaluation of Dimpled Exenatide Loaded PLGA Microparticles Prepared by Ultra-Fine Particle Processing System

AAPS PharmSciTech. 2019 Jan 9;20(2):64. doi: 10.1208/s12249-018-1208-8.

Abstract

Spherical poly (D, L-lactic-co-glycolic acid) microparticles (PLGA-MPs) have long been investigated in order to achieve sustained delivery of proteins/peptides. However, the formation mechanism and release characteristics of the specific shape MPs were still unknown. This study aimed to develop a novel-dimpled exenatide-loaded PLGA-MPs (Exe-PLGA-MPs) using an ultra-fine particle processing system (UPPS) and investigate the formation mechanism and release characteristics. Exe-PLGA-MPs were prepared by UPPS and optimized based on their initial burst within the first 24 h and drug release profiles. Physicochemical properties of Exe-PLGA-MPs, including morphology, particle size, and structural integrity of Exe extracted from Exe-PLGA-MPs, were evaluated. Furthermore, pharmacokinetic studies of the optimal formulation were conducted in Sprague-Dawley (SD) rats to establish in vitro-in vivo correlations (IVIVC) of drug release. Exe-PLGA-MPs with dimpled shapes and uniform particle sizes achieved a high encapsulation efficiency (EE%, 91.50 ± 2.65%) and sustained drug release for 2 months in vitro with reduced initial burst (20.42 ± 1.64%). Moreover, the pharmacokinetic studies revealed that effective drug concentration could be maintained for 3 weeks following a single injection of dimpled Exe-PLGA-MPs with high IVIVC. Dimpled PLGA-MPs prepared using the UPPS technique could thus have great potential for sustained delivery of macromolecular proteins/peptides.

Keywords: dimpled; drug release; exenatide; pharmacokinetics; ultra-fine particle processing system (UPPS).

MeSH terms

  • Animals
  • Chemistry, Pharmaceutical / methods*
  • Delayed-Action Preparations / chemical synthesis
  • Delayed-Action Preparations / pharmacokinetics
  • Drug Evaluation, Preclinical / methods
  • Drug Liberation
  • Exenatide / chemical synthesis*
  • Exenatide / pharmacokinetics
  • Hypoglycemic Agents / chemical synthesis
  • Hypoglycemic Agents / pharmacokinetics
  • Male
  • Microspheres*
  • Particle Size
  • Polylactic Acid-Polyglycolic Acid Copolymer / chemical synthesis*
  • Polylactic Acid-Polyglycolic Acid Copolymer / pharmacokinetics
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Delayed-Action Preparations
  • Hypoglycemic Agents
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Exenatide